HomeNews

Photocure ASA: Annual report 2012

Published: 1 October 2013Financial Investment & Stock




The annual report for Photocure ASA (the "Company") for 2012 has previously been made available at the Company's web page: http://www.photocure.com/Investor-relations/, and is now also published on www.newsweb.no.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no
www.photocure.com

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events

PRESS-RELEASE
European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care
Oslo, Norway
8 April 2024
PRESS-RELEASE
Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference
Oslo, Norway
5 April 2024
NEWS POST
EAU 2024: Photocure Partner Asieris to present the Drug and Equipment Performance Results from the Chinese Phase III Clinical Study of Hexvix in Combination with HD 4K Blue Light Cystoscopy equipment
Oslo, Norway
1 April 2024
PRESS-RELEASE
New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
Oslo, Norway
28 March 2024
NEWS POST
Canadian Health Authorities approve updated and expanded label for Cysview
Oslo, Norway
22 March 2024
PRESS-RELEASE
Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
Oslo, Norway
18 March 2024
PRESS-RELEASE
Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO
Oslo, Norway
23 February 2024
PRESS-RELEASE
Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
Oslo, Norway
22 February 2024
OSE Notice
Photocure ASA: Results for the fourth quarter of 2023
Oslo, Norway
21 February 2024
OSE Notice
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results
Oslo, Norway
19 February 2024
NEWS POST
New Photocure White Paper addressing Inequality in Bladder Cancer Care and the importance of Real World Evidence
Oslo, Norway
1 February 2024
PRESS-RELEASE
Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024
Oslo, Norway
29 January 2024
OSE Notice
Photocure ASA – Share option grant
Oslo, Norway
21 December 2023
NEWS POST
Photocure Partner Asieris to present unpublished clinical trial and real-world data on Hexvix in China at ASCO GU 2024
Oslo, Norway
15 December 2023
PRESS-RELEASE
SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy
Oslo, Norway
1 December 2023
PRESS-RELEASE
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
Oslo, Norway
29 November 2023
GLOBAL HEADQUARTERS

Photocure ASA
Hoffsveien 4
0275 Oslo
Norway

E-mail: info@photocure.no
NORTH AMERICA

Photocure INC
202 Carnegie Center
Suite 101, Princeton,
NJ 08540, USA

E-mail: info@photocure.com
EUROPE

Photocure GmbH 
Breite Str. 27 
40213 Düsseldorf 
Germany

E-mail: kontakt@photocure.com
Follow us
Privacy PolicyTerms of use
© Photocure 2024